[Evaluation of breast HER2+ cancer pathologic response after a taxan plus trastuzumab-based chemotherapy]
L Komguem1, P Guilbert2, M Doublier3
1Alix de champagne, service de gynécologie-obstétrique, CHU de Reims, 45, rue Cognaq-Jay, 51100 Reims, France.
Objectives:
In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.
Methods:
Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on logiciel XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.
Results:
The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67>44%.
Conclusion:
The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67>44%.
